Silence Therapeutics plc (SLNCF)
OTCMKTS · Delayed Price · Currency is USD
2.360
0.00 (0.00%)
May 5, 2026, 4:00 PM EST
Silence Therapeutics Revenue
In the year 2025, Silence Therapeutics had annual revenue of $559.00K, down -98.71%. Silence Therapeutics had revenue of $34.00K in the quarter ending December 31, 2025, a decrease of -99.86%.
Revenue
559.00K
Revenue Growth
-98.65%
P/S Ratio
621.90
Revenue / Employee
6.35K
Employees
88
Market Cap
347.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 559.00K | -42.70M | -98.71% |
| Dec 31, 2024 | 43.26M | 11.62M | 36.71% |
| Dec 31, 2023 | 31.64M | 9.99M | 46.12% |
| Dec 31, 2022 | 21.66M | 4.87M | 29.01% |
| Dec 31, 2021 | 16.79M | 9.29M | 124.07% |
| Dec 31, 2020 | 7.49M | 7.17M | 2,215.11% |
| Dec 31, 2019 | 323.57K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 21.62K | -928.69K | -97.72% |
| Dec 31, 2016 | 950.31K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 23.37K | -170.40K | -87.94% |
| Dec 31, 2013 | 193.77K | -70.63K | -26.71% |
| Dec 31, 2012 | 264.40K | -812.57K | -75.45% |
| Dec 31, 2011 | 1.08M | -2.61M | -70.75% |
| Dec 31, 2010 | 3.68M | 893.28K | 32.03% |
| Dec 31, 2009 | 2.79M | -435.52K | -13.51% |
| Dec 31, 2008 | 3.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSilence Therapeutics News
- 2 months ago - Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 5 months ago - Silence Therapeutics Announces Leadership Changes - Business Wire
- 6 months ago - Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Business Wire
- 6 months ago - Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 6 months ago - Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) - Business Wire
- 8 months ago - Silence Therapeutics to Participate in September Investor Conferences - Business Wire
- 9 months ago - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 11 months ago - Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera - Business Wire